Compare LUMN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | GRFS |
|---|---|---|
| Founded | 1968 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.2B |
| IPO Year | 1994 | 2008 |
| Metric | LUMN | GRFS |
|---|---|---|
| Price | $3.93 | $8.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $5.92 | ★ $10.37 |
| AVG Volume (30 Days) | ★ 14.7M | 721.2K |
| Earning Date | 11-04-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,402,000,000.00 | N/A |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | N/A | $6.15 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.84 | $6.96 |
| 52 Week High | $11.30 | $9.77 |
| Indicator | LUMN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 47.67 |
| Support Level | $3.84 | $7.52 |
| Resistance Level | $6.87 | $8.36 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 7.05 | 11.39 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprise services, which account for about 85%-90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.